31 related articles for article (PubMed ID: 16890725)
1. Synergistic antitumor effects of interleukin-12 gene transfer and systemic administration of interleukin-18 in a mouse bladder cancer model.
Yamanaka K; Hara I; Nagai H; Miyake H; Gohji K; Micallef MJ; Kurimoto M; Arakawa S; Kamidono S
Cancer Immunol Immunother; 1999 Sep; 48(6):297-302. PubMed ID: 10473804
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of neuroblastoma by an Interleukin-21-secreting cell vaccine involves survivin as antigen.
Croce M; Meazza R; Orengo AM; Fabbi M; Borghi M; Ribatti D; Nico B; Carlini B; Pistoia V; Corrias MV; Ferrini S
Cancer Immunol Immunother; 2008 Nov; 57(11):1625-34. PubMed ID: 18324400
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model.
Sato R; Watanabe K; Matsushita Y; Watanabe H; Tamura K; Motoyama D; Otsuka A; Miyake H
Anticancer Res; 2024 Apr; 44(4):1417-1423. PubMed ID: 38537988
[TBL] [Abstract][Full Text] [Related]
4. The past, present, and future of immunotherapy for bladder tumors.
Schneider T; Zhao L; Zhu Z; Gabrielyan G; Xiao H; Fajardo ED; Bai Q; Wakefield MR; Fang Y
Med Oncol; 2022 Sep; 39(12):236. PubMed ID: 36175715
[TBL] [Abstract][Full Text] [Related]
5. IL-21 receptor signaling is essential for control of hepatocellular carcinoma growth and immunological memory for tumor challenge.
Zheng X; Zhou Y; Yi X; Chen C; Wen C; Ye G; Li X; Tang L; Zhang X; Yang F; Liu G; Li Y; Hou J
Oncoimmunology; 2018; 7(12):e1500673. PubMed ID: 30524894
[TBL] [Abstract][Full Text] [Related]
6. IL-21: a pleiotropic cytokine with potential applications in oncology.
Croce M; Rigo V; Ferrini S
J Immunol Res; 2015; 2015():696578. PubMed ID: 25961061
[TBL] [Abstract][Full Text] [Related]
7. Immunological basis in the pathogenesis and treatment of bladder cancer.
Thompson DB; Siref LE; Feloney MP; Hauke RJ; Agrawal DK
Expert Rev Clin Immunol; 2015 Feb; 11(2):265-79. PubMed ID: 25391391
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer.
Zhu Z; Shen Z; Xu C
Mediators Inflamm; 2012; 2012():528690. PubMed ID: 22811589
[TBL] [Abstract][Full Text] [Related]
9. Involvement of interleukin-21 in the regulation of colitis-associated colon cancer.
Stolfi C; Rizzo A; Franzè E; Rotondi A; Fantini MC; Sarra M; Caruso R; Monteleone I; Sileri P; Franceschilli L; Caprioli F; Ferrero S; MacDonald TT; Pallone F; Monteleone G
J Exp Med; 2011 Oct; 208(11):2279-90. PubMed ID: 21987656
[TBL] [Abstract][Full Text] [Related]
10. Cytokines as Adjuvants for Vaccine and Cellular Therapies for Cancer.
Capitini CM; Fry TJ; Mackall CL
Am J Immunol; 2009 Jan; 5(3):65-83. PubMed ID: 20182648
[TBL] [Abstract][Full Text] [Related]
11. Involvement of ERK-1/2 in IL-21-induced cytokine production in leukemia cells and human monocytes.
Fuqua CF; Akomeah R; Price JO; Adunyah SE
Cytokine; 2008 Oct; 44(1):101-7. PubMed ID: 18707899
[TBL] [Abstract][Full Text] [Related]
12. Role of IL-21 in immune-regulation and tumor immunotherapy.
di Carlo E; de Totero D; Piazza T; Fabbi M; Ferrini S
Cancer Immunol Immunother; 2007 Sep; 56(9):1323-34. PubMed ID: 17447063
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 21 therapy increases the density of tumor infiltrating CD8+ T cells and inhibits the growth of syngeneic tumors.
Søndergaard H; Frederiksen KS; Thygesen P; Galsgaard ED; Skak K; Kristjansen PE; Odum N; Kragh M
Cancer Immunol Immunother; 2007 Sep; 56(9):1417-28. PubMed ID: 17285290
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-21 gene transfection into mouse bladder cancer cells results in tumor rejection through the cytotoxic T lymphocyte response.
Furukawa J; Hara I; Nagai H; Yao A; Oniki S; Fujisawa M
J Urol; 2006 Sep; 176(3):1198-203. PubMed ID: 16890725
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-21 activates cytotoxic T lymphocytes and natural killer cells to generate antitumor response in mouse renal cell carcinoma.
Kumano M; Hara I; Furukawa J; Oniki S; Nagai H; Miyake H; Fujisawa M
J Urol; 2007 Oct; 178(4 Pt 1):1504-9. PubMed ID: 17707061
[TBL] [Abstract][Full Text] [Related]
16. Antitumor effect of simultaneous transfer of interleukin-12 and interleukin-18 genes and its mechanism in a mouse bladder cancer model.
Hikosaka S; Hara I; Miyake H; Hara S; Kamidono S
Int J Urol; 2004 Aug; 11(8):647-52. PubMed ID: 15285756
[TBL] [Abstract][Full Text] [Related]
17. IL-23 gene therapy for mouse bladder tumour cell lines.
Kuramoto T; Fujii R; Nagai H; Belladonna ML; Yoshimoto T; Kohjimoto Y; Inagaki T; Hara I
BJU Int; 2011 Sep; 108(6):914-21. PubMed ID: 21435151
[TBL] [Abstract][Full Text] [Related]
18. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-induced tumor immunogenicity.
Cavallo F; Giovarelli M; Gulino A; Vacca A; Scala G; Forni G
Immunol Ser; 1994; 61():183-93. PubMed ID: 8011743
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
